Ovid Therapeutics To Sell Future Royalties Of Ganaxolone For $7 Mln In Cash, Stock Up In Pre-Market

Ovid Therapeutics Inc. (OVID) has announced a $7 million cash deal to sell future royalties and global intellectual property rights for its ganaxolone drug to Immedica Pharma AB. This transaction provides Ovid with a crucial capital infusion to support ongoing operations, while Immedica strengthens its strategic focus on ganaxolone, an adjunctive treatment for epileptic seizures, with potential for expanded indications. Following the announcement, OVID shares saw a pre-market increase of 7.39%.

Analysis

Ovid Therapeutics Inc. has executed a strategic transaction to bolster its financial position, selling future royalties and global intellectual property for its ganaxolone drug to Immedica Pharma AB for $7 million in cash. This deal provides a crucial, non-dilutive capital infusion stated to support Ovid's ongoing operations, suggesting a move to extend its operational runway and de-risk its near-term balance sheet. For Immedica, the acquisition strengthens its strategic commitment to ganaxolone, an adjunctive treatment for epileptic seizures, by consolidating control and securing rights for additional indications. The market has interpreted this development favorably, as evidenced by a 7.39% pre-market increase in OVID's stock price to $0.32, indicating that investors value the immediate certainty of the cash injection over the speculative, long-term royalty stream from this single asset.

Key Decisions for Investors

• Investors should recognize the $7 million cash infusion as a significant positive for Ovid's short-term financial stability, as it extends the company's operational runway without diluting existing shareholders.
• The divestment of ganaxolone's future royalties means Ovid's long-term valuation is now entirely dependent on the success of its remaining clinical pipeline, which requires a renewed focus for due diligence.
• Consider the trade-off: while the immediate risk is lowered, the company has capped its upside from a potentially valuable commercial asset, a factor that must be weighed against the potential of its other programs.